Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine
- 18 October 2005
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (11), 1356-1365
- https://doi.org/10.1111/j.1368-5031.2005.00692.x
Abstract
Almotriptan is a 5-HT(1B/1D) receptor agonist, or triptan, indicated for the acute treatment of migraine. It has been shown to be effective and well tolerated for the treatment of acute migraine in approximately 5000 patients enrolled in short-term placebo- and active-controlled trials and long-term open-label trials. A recent meta-analysis reported that almotriptan has the highest sustained pain-free (SPF) rate and lowest adverse-event (AE) rate of all oral triptans. Sustained pain free is a composite endpoint of pain freedom at 2 h, no recurrence of moderate-to-severe headache and no use of rescue medication from 2 to 24 h after dosing. Patient surveys have indicated that migraine sufferers consider complete pain relief, no recurrence, rapid onset and no side-effects to be the most important attributes of their acute treatment. Composite endpoints such as SPF and SPF with no AEs (SNAE) contain the attributes that migraine sufferers express as being the most important elements of an acute migraine therapy, and their use in future clinical trials should aid in the selection of agents that can offer patients the highest likelihood of consistent treatment success.Keywords
This publication has 64 references indexed in Scilit:
- Consistent Efficacy, Tolerability, and High Levels of Satisfaction With Almotriptan 12.5 mg When Used to Treat Multiple Migraine Attacks in Routine Clinical PracticeHeadache: The Journal of Head and Face Pain, 2005
- Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase IIICurrent Medical Research and Opinion, 2004
- Defeating migraine pain with triptans: A race against the development of cutaneous allodyniaAnnals of Neurology, 2003
- A review of the clinical efficacy and tolerability of almotriptan in acute migraineExpert Opinion on Pharmacotherapy, 2003
- Tolerability of the TriptansDrug Safety, 2003
- Vascular Effects of the New Anti-Migraine Agent Almotriptan on Human Cranial and Peripheral ArteriesCephalalgia, 2001
- Preference Comparison of Rizatriptan ODT 10‐mg and Sumatriptan 50‐mg Tablet in MigraineHeadache: The Journal of Head and Face Pain, 2001
- Triptans in MigraineDrugs, 2000
- An association between migraine and cutaneous allodyniaAnnals of Neurology, 2000
- Healthcare Resource and Lost Labour Costs of Migraine Headache in the USPharmacoEconomics, 1992